Ascletis Pharma Inc. (1672) reported multiple upcoming poster presentations on its small molecule and peptide obesity programs at ObesityWeek® 2025 in Atlanta, Georgia, scheduled from November 4 to 7, 2025.

Several key studies will be featured during the event. The first is a full analysis of a 28-day multiple ascending dose study of ASC30, a GLP-1 receptor biased small molecule agonist under both oral tablet and subcutaneous injection development pathways. Additional information will include once-monthly and once-quarterly formulations of ASC30. Another presentation focuses on a Phase Ib study of ASC30 as a once-monthly subcutaneous injection in participants with obesity.

Also highlighted is the combination therapy of ASC31 and ASC47. ASC31 targets both GLP-1 and GIP receptors, while ASC47 is a thyroid hormone receptor beta selective small molecule agonist designed for adipose targeting. Both candidates demonstrated notable preclinical data showing significant weight loss potential when administered together.

Ascletis Pharma Inc. noted that these investigational products are protected by patent portfolios and represent an ongoing effort to advance potential treatment options for obesity. The company cautioned that development, manufacturing, and commercialization of these products are subject to various uncertainties.